Table 2.

Several inhibitors targeting the Wnt, Hedgehog and Notch signaling pathways in clinical trials

Compound	Target	Tumor type	Phase state	Efficacy outcomes
LGK974 [37]	Wnt	Metastatic colorectal cancer	Phase I (NCT02278133)	N/A
ETC-159 [38]	Wnt	Solid tumor	Phase I (NCT02521844)	Recruiting
PRI-724 [39]	Wnt	Advanced pancreatic cancer	Phase I (NCT01764477)	Stable disease rate: 40%
MK-0752 [40]	Notch	T cell acute lymphoblastic leukemia	Phase I (NCT00100152)	Terminated
LY-900,009 [41]	Notch	Advanced cancer	Phase I (NCT01158404)	Stable disease in 5 patients from dose escalation group
RO4929097 [42]	Notch	Advanced-stage solid tumors	Phase I	Partial response in 1 of 96 evaluable patients, Stable disease in 28 of 96 patients
BMS-906,024 [43]	Notch	Advanced cancer	Phase I (NCT01986218)	Terminated
Nirogacestat [44]	Notch	1.Metastatic Cancer Pancreas 2.Desmoid tumors	Phase II (NCT02109445)	1.Terminated 2.Confirmed partial response in 5 patients, stable disease in anoth -er patients
Patidegib [45]	Hedgehog	Basal cell nevus syndrome; skin cancer	Phase II (NCT02762084)	Terminated
BMS-833,923 [46]	Hedgehog	Leukemia	Phase I/II (NCT01218477)	N/A
Taladegib [47]	Hedgehog	Advanced cancer	Phase I/II (NCT01226485)	Stable disease rate: 30.9%,Objective respo -nse rate: 26.2%